Highlights of contemporary issues in the medical management of prostate cancer
- 1 August 2002
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 43 (2) , 105-121
- https://doi.org/10.1016/s1040-8428(02)00023-9
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- The selective endothelin-a receptor antagonist improves quality of life (QOL) weighted time to progression in hormone refractory prostate cancer patientsEuropean Journal Of Cancer, 2001
- BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancerEuropean Journal Of Cancer, 2001
- Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patientsEuropean Journal Of Cancer, 2001
- Open-label phase II study of ZD0473 in patients with metastatic hormone refractory prostate cancerEuropean Journal Of Cancer, 2001
- A phase dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (HRPC)European Journal Of Cancer, 2001
- COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?Journal of Urology, 2000
- 4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate CancerEuropean Urology, 2000
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Early Androgen Deprivation for Prostate Cancer?New England Journal of Medicine, 1999